
Claims

1. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis in a patient in need thereof, wherein Formula I is represented by:



and wherein the patient is orally administered a compound of Formula I at a daily amount ranging from 75 mg to 100 mg or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I or a pharmaceutically acceptable salt thereof is administered twice per day, and wherein

(i) the patient has consumed food within 1 hour prior to receiving said compound;

(ii) the administering is performed at a time the patient consumes a meal; or

(iii) the patient consumes a meal within 1 hour after receiving said compound.

2. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount ranging from 85 mg to 95 mg or a pharmaceutically acceptable salt thereof.


3. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount of about 90 mg or a pharmaceutically acceptable salt thereof.

4. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount of 90 mg or a pharmaceutically acceptable salt thereof.

5. The use of claim 1, wherein the medicament is to be orally administered twice per day as a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of about 45 mg or a pharmaceutically acceptable salt thereof.

6. The use of claim 1, wherein the medicament is to be orally administered twice per day as a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of 45 mg or a pharmaceutically acceptable salt thereof.

7. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis, wherein the medicament is to be orally administered to a patient in need thereof two times per day as a unit dosage containing the compound in an amount ranging from 25 mg to 50 mg or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:



,

and wherein

(i) the patient has consumed food within 2 hours prior to receiving the unit dosage;

(ii) said administering is performed at the time the patient consumes a meal; or

(iii) the patient consumes food within 30 minutes after receiving the unit dosage.

8. The use of claim 7, wherein the unit dosage is to be administered to the patient in the form of two unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

9. The use of claim 7, wherein the unit dosage is to be administered to the patient in the form of a single unit formulation containing compound of Formula I or a pharmaceutically acceptable salt thereof.


10. The use of any one of claims 7-9, wherein the unit formulation(s) are in the form of a tablet or capsule.

11. The use of any one of claims 7-10, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.

12. The use of any one of claims 7-11, wherein a first unit dosage is to be administered to the patient in the morning, and a second unit dosage is to be administered to the patient in the evening.

13. The use of any one of claims 7-12, wherein the patient has consumed food within 1 hour prior to receiving the unit dosage.

14. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis, wherein the medicament is to be orally administered to a patient in need thereof twice daily as a unit dosage containing the compound in an amount of about 45 mg or a pharmaceutically acceptable salt thereof, wherein the patient consumes a meal within 1 hour after the administration, and Formula I is represented by:



15. The use of claim 14, wherein the unit dosage is to be administered to the patient in the form of one or more unit formulations containing the compound of Formula I or a pharmaceutically acceptable salt thereof.

16. The use of claim 15, wherein the unit formulation(s) are in the form of a tablet or capsule.

17. The use of any one of claims 14-16, wherein the unit dosage contains about 45 mg of compound of Formula I.

18. The use of any one of claims 14-16, wherein the unit dosage contains 45 mg of compound of Formula I.

19. The use of any one of claims 14-18, wherein the medicament is to be administered at the time the patient consumes a meal.

20. The use of any one of claims 14-19, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.

21. The compound for use of any one of claims 14-20, wherein a first unit dosage is administered to the patient in the morning, and a second unit dosage is administered to the patient in the evening.

22. The compound for use of any one of claims 14-18, wherein a first unit dosage is administered to the patient at the time the patient consumes a breakfast meal in the morning, and a second unit dosage is administered to the patient at the time the patient consumes a dinner meal in the evening.

23. The compound for use of any one of claims 14-22, wherein the patient receives the unit dosage two times per day for a duration of at least 2 weeks.

24. The compound for use of any one of claims 14-22, wherein the patient receives the unit dosage two times per day for a duration of at least 1 month.

25. The compound for use of any one of claims 14-22, wherein the patient receives the unit dosage two times per day for a duration of at least 6 months.

26. The compound for use of any one of claims 1-17, wherein the multiple sclerosis is relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, or progressive-relapsing multiple sclerosis.

27. The compound for use of any one of claims 1-26, wherein the multiple sclerosis is relapsing multiple sclerosis.

28. The compound for use of any one of claims 1-27, wherein the patient is an adult human.

29. The compound for use of any one of claims 1-28, wherein the patient is in a fed state when the compound of Formula I or pharmaceutically acceptable salt thereof is administered to the patient.